Rita I. L. Catarino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rita I. L. Catarino has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Adriana M. Pimenta
FCS-UFP—Health Sciences Faculty, University Fernando Pessoa, 4249-004 Porto, Portugal
12 shared publications - Maria Fernanda C. Leal
FCS-UFP—Health Sciences Faculty, University Fernando Pessoa, 4249-004 Porto, Portugal
10 shared publications - Maria Renata S. Souto
FCS-UFP—Health Sciences Faculty, University Fernando Pessoa, 4249-004 Porto, Portugal
10 shared publications Adriana M. Pimenta
3 shared publications- José Luis Fontes Costa Lima
LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
3 shared publications M. Renata S. Souto
3 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by MDPI AG in Pollutants
- Vol. 6 (4) , 56
The Nitrate Paradox in Vegetables: Balancing Health Benefits and Toxicological Risks
Vegetables are essential components of a healthy diet and represent the primary source of dietary nitrate exposure in humans, accounting for approximately 80% of total intake. The use of nitrogen fertilizers and the ability of some plant species to accumulate nitrate contribute to high concentrations of this compound in certain vegetables. Traditionally, nitrate has been regarded as an undesirable contaminant because of its conversion into nitrite, which may induce methemoglobinemia in vulnerable populations, particularly infants, and contribute to the formation of potentially carcinogenic N-nitroso compounds (NOCs). However, growing evidence has highlighted the beneficial role of the nitrate-nitrite-nitric oxide pathway, particularly when nitrate is consumed through vegetables, whose antioxidant-rich matrix may limit N-nitrosamine formation and promote beneficial effects on cardiovascular health, exercise performance, cognitive function, and metabolic regulation. This review critically examines the current literature on nitrate in vegetables, integrating its physiological benefits with established toxicological concerns. It also discusses factors influencing nitrate concentrations, regulatory limits, and exposure risks. Available evidence supports a balanced risk/benefit perspective on vegetable-derived nitrate intake. However, post-harvest handling, culinary practices, and dietary context are essential to favor nitric oxide formation over nitrosation, maximizing potential health benefits while ensuring food safety and public health protection.
- 2 October 2026
- Published by MDPI AG in Pollutants
- Vol. 6 (4) , 56
Open AccessThe Nitrate Paradox in Vegetables: Balancing Health Benefits and Toxicological Risks
Vegetables are essential components of a healthy diet and represent the primary source of dietary nitrate exposure in humans, accounting for approximately 80% of total intake. The use of nitrogen fertilizers and the ability of some plant species to accumulate nitrate contribute to high concentrations of this compound in certain vegetables. Traditionally, nitrate has been regarded as an undesirable contaminant because of its conversion into nitrite, which may induce methemoglobinemia in vulnerable populations, particularly infants, and contribute to the formation of potentially carcinogenic N-nitroso compounds (NOCs). However, growing evidence has highlighted the beneficial role of the nitrate-nitrite-nitric oxide pathway, particularly when nitrate is consumed through vegetables, whose antioxidant-rich matrix may limit N-nitrosamine formation and promote beneficial effects on cardiovascular health, exercise performance, cognitive function, and metabolic regulation. This review critically examines the current literature on nitrate in vegetables, integrating its physiological benefits with established toxicological concerns. It also discusses factors influencing nitrate concentrations, regulatory limits, and exposure risks. Available evidence supports a balanced risk/benefit perspective on vegetable-derived nitrate intake. However, post-harvest handling, culinary practices, and dietary context are essential to favor nitric oxide formation over nitrosation, maximizing potential health benefits while ensuring food safety and public health protection.
- Open Access
- 6 September 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (17) , 8855
Bridging the Gap Between Biological Potential and Clinical Efficacy of Topical Resveratrol: Advanced Delivery Systems and Nanotechnology-Based Approaches
Resveratrol (RSV) is a naturally occurring polyphenol with well-documented antioxidant, anti-inflammatory, antimicrobial, photoprotective, wound-healing, depigmenting, and anticancer properties, making it an attractive candidate for dermocosmetic and dermatological applications. However, its clinical translation into effective topical products remains limited by poor aqueous solubility, chemical instability, photoisomerization, rapid cutaneous metabolism, and restricted skin penetration, all of which compromise local bioavailability and therapeutic efficacy. This narrative review critically examines the molecular mechanisms underlying the cutaneous effects of RSV and discusses how its physicochemical and pharmacokinetic characteristics influence topical performance. Particular emphasis is placed on advanced delivery strategies developed to overcome these limitations, including lipid-based nanocarriers, polymeric nanoparticles (NPs), nanofibers, inorganic nanocarriers, microneedles, hydrogels, and other emerging delivery platforms. The mechanisms by which these systems improve RSV solubility, stability, controlled release, skin retention, and dermal penetration are critically evaluated together with their reported therapeutic outcomes. Although advanced delivery systems have consistently improved the topical performance of RSV in preclinical studies, clinical evidence remains limited. To date, only one published placebo-controlled clinical trial has specifically evaluated topical RSV as the active ingredient, and none of the advanced RSV-nanocarrier platforms discussed in this review has undergone clinical evaluation. Bridging this substantial translational gap will require not only further optimization of formulation design but also scalable manufacturing, rigorous clinical validation, and regulatory pathways capable of supporting the development of safe, effective and evidence-based next-generation dermocosmetic and dermatological products.
- 6 September 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (17) , 8855
Open AccessBridging the Gap Between Biological Potential and Clinical Efficacy of Topical Resveratrol: Advanced Delivery Systems and Nanotechnology-Based Approaches
Resveratrol (RSV) is a naturally occurring polyphenol with well-documented antioxidant, anti-inflammatory, antimicrobial, photoprotective, wound-healing, depigmenting, and anticancer properties, making it an attractive candidate for dermocosmetic and dermatological applications. However, its clinical translation into effective topical products remains limited by poor aqueous solubility, chemical instability, photoisomerization, rapid cutaneous metabolism, and restricted skin penetration, all of which compromise local bioavailability and therapeutic efficacy. This narrative review critically examines the molecular mechanisms underlying the cutaneous effects of RSV and discusses how its physicochemical and pharmacokinetic characteristics influence topical performance. Particular emphasis is placed on advanced delivery strategies developed to overcome these limitations, including lipid-based nanocarriers, polymeric nanoparticles (NPs), nanofibers, inorganic nanocarriers, microneedles, hydrogels, and other emerging delivery platforms. The mechanisms by which these systems improve RSV solubility, stability, controlled release, skin retention, and dermal penetration are critically evaluated together with their reported therapeutic outcomes. Although advanced delivery systems have consistently improved the topical performance of RSV in preclinical studies, clinical evidence remains limited. To date, only one published placebo-controlled clinical trial has specifically evaluated topical RSV as the active ingredient, and none of the advanced RSV-nanocarrier platforms discussed in this review has undergone clinical evaluation. Bridging this substantial translational gap will require not only further optimization of formulation design but also scalable manufacturing, rigorous clinical validation, and regulatory pathways capable of supporting the development of safe, effective and evidence-based next-generation dermocosmetic and dermatological products.
- Open Access
- 18 June 2026
- Published by Fernando Pessoa Health School in Athena Health & Research Journal
- Vol. 3 (Suppl. 2)
Tirzepatide: a new treatment for obesity - literature review
Introduction: Obesity is defined by the World Health Organization as “excessive fat accumulation that poses a health risk” and is associated with type 2 diabetes mellitus and cardiovascular disease. GLP-1 receptor agonists improved weight and glycaemic control, leading to development of dual GIP/GLP-1 agonists (twincretins). Tirzepatide was approved in 2022 for glycaemic control in type 2 diabetes mellitus and in 2023 for obesity treatment. Objectives: To review the efficacy and safety of tirzepatide in obesity with or without type 2 diabetes mellitus, focusing on clinical trials and weight loss outcomes. Methodology: A narrative review was conducted between October 2022 and February 2026 using PubMed, ScienceDirect, b-on, Google Scholar, and ClinicalTrials.gov. The terms “Obesity,” “Tirzepatide,” “GIP,” “GLP-1,” “Twincretin,” and “Anti-obesity medication” were combined with Boolean operators. Of 283 articles identified, 37 were selected after screening and full-text review. Phase III randomized clinical trials (2021–2025) in adults with overweight or obesity, with or without type 2 diabetes mellitus, were included, focusing on the SURPASS and SURMOUNT programmes. Results: In SURPASS trials, tirzepatide 5–15 mg weekly in type 2 diabetes mellitus reduced weight (5–11 kg), HbA1c (up to 2.8%), and improved cardiometabolic parameters. SURMOUNT showed weight loss of 13–22% in obesity, greater in non-diabetic individuals, benefit with lifestyle intervention, weight regain after discontinuation, and superiority versus semaglutide 2.4 mg. Safety was favorable, with mainly mild to moderate gastrointestinal adverse events and discontinuation rates similar to other incretin therapies. Conclusion: Tirzepatide is an effective option for obesity, with consistent weight loss and metabolic benefits in patients with and without type 2 diabetes mellitus and a favorable safety profile. Evidence suggests clinical relevance and potential shift in treatment paradigm, although long-term data are needed. A triple agonist targeting GIP/GLP-1/glucagon receptors is under investigation.
- 18 June 2026
- Published by Fernando Pessoa Health School in Athena Health & Research Journal
- Vol. 3 (Suppl. 2)
Open AccessTirzepatide: a new treatment for obesity - literature review
Introduction: Obesity is defined by the World Health Organization as “excessive fat accumulation that poses a health risk” and is associated with type 2 diabetes mellitus and cardiovascular disease. GLP-1 receptor agonists improved weight and glycaemic control, leading to development of dual GIP/GLP-1 agonists (twincretins). Tirzepatide was approved in 2022 for glycaemic control in type 2 diabetes mellitus and in 2023 for obesity treatment. Objectives: To review the efficacy and safety of tirzepatide in obesity with or without type 2 diabetes mellitus, focusing on clinical trials and weight loss outcomes. Methodology: A narrative review was conducted between October 2022 and February 2026 using PubMed, ScienceDirect, b-on, Google Scholar, and ClinicalTrials.gov. The terms “Obesity,” “Tirzepatide,” “GIP,” “GLP-1,” “Twincretin,” and “Anti-obesity medication” were combined with Boolean operators. Of 283 articles identified, 37 were selected after screening and full-text review. Phase III randomized clinical trials (2021–2025) in adults with overweight or obesity, with or without type 2 diabetes mellitus, were included, focusing on the SURPASS and SURMOUNT programmes. Results: In SURPASS trials, tirzepatide 5–15 mg weekly in type 2 diabetes mellitus reduced weight (5–11 kg), HbA1c (up to 2.8%), and improved cardiometabolic parameters. SURMOUNT showed weight loss of 13–22% in obesity, greater in non-diabetic individuals, benefit with lifestyle intervention, weight regain after discontinuation, and superiority versus semaglutide 2.4 mg. Safety was favorable, with mainly mild to moderate gastrointestinal adverse events and discontinuation rates similar to other incretin therapies. Conclusion: Tirzepatide is an effective option for obesity, with consistent weight loss and metabolic benefits in patients with and without type 2 diabetes mellitus and a favorable safety profile. Evidence suggests clinical relevance and potential shift in treatment paradigm, although long-term data are needed. A triple agonist targeting GIP/GLP-1/glucagon receptors is under investigation.
- Open Access
- 8 April 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (2) , 29
Three Decades of Taxanes: Exploring the Next Frontier
Taxanes, such as paclitaxel and docetaxel, are microtubule-stabilizing agents widely used in oncology, either as monotherapy or in combination regimens. While highly effective, these first-generation taxanes face important limitations, including significant toxicity, reduced water solubility, and the emergence of multidrug resistance. To address these challenges, semi-synthetic taxoids have been developed, aiming to improve pharmacological profiles and overcome therapeutic barriers. Central to these efforts is the understanding of structure-activity relationships, which guides the rational design of taxane analogues with enhanced efficacy and safety. This review explores recent advances in taxoid development, highlights findings from clinical trials, and evaluates how these new agents compare with traditional taxanes in terms of therapeutic potential and tolerability. While novel delivery systems offer improved outcomes with existing drugs, the development of new taxane analogues remains a promising approach to address drug resistance, albeit with challenges related to toxicity, high costs, and historically low success rates in drug development. Furthermore, taxanes are already used in certain cardiovascular conditions and show emerging potential in neurodegenerative diseases, although current evidence remains largely limited to preclinical or early-phase clinical studies. These developments mark an important evolution in the field and offer new opportunities for future therapeutic strategies.
- 8 April 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (2) , 29
Open AccessThree Decades of Taxanes: Exploring the Next Frontier
Taxanes, such as paclitaxel and docetaxel, are microtubule-stabilizing agents widely used in oncology, either as monotherapy or in combination regimens. While highly effective, these first-generation taxanes face important limitations, including significant toxicity, reduced water solubility, and the emergence of multidrug resistance. To address these challenges, semi-synthetic taxoids have been developed, aiming to improve pharmacological profiles and overcome therapeutic barriers. Central to these efforts is the understanding of structure-activity relationships, which guides the rational design of taxane analogues with enhanced efficacy and safety. This review explores recent advances in taxoid development, highlights findings from clinical trials, and evaluates how these new agents compare with traditional taxanes in terms of therapeutic potential and tolerability. While novel delivery systems offer improved outcomes with existing drugs, the development of new taxane analogues remains a promising approach to address drug resistance, albeit with challenges related to toxicity, high costs, and historically low success rates in drug development. Furthermore, taxanes are already used in certain cardiovascular conditions and show emerging potential in neurodegenerative diseases, although current evidence remains largely limited to preclinical or early-phase clinical studies. These developments mark an important evolution in the field and offer new opportunities for future therapeutic strategies.
- Open Access
- 10 September 2025
- Published by MDPI AG in Pollutants
- Vol. 5 (3) , 29
Heavy Metals in Milk and Dairy Products: Safety and Analysis
Milk and dairy products play a key role in the human diet but may also be vehicles for toxic contaminants, particularly heavy metals and metalloids (HMs), such as lead (Pb), cadmium (Cd), mercury (Hg), and arsenic (As). This integrative review examines peer-reviewed studies published between 2015 and 2025 to examine sources, occurrence, and health risks associated with HM contamination in milk and dairy products. Key sources include industrial emissions, agricultural runoff, contaminated feed and water, and inadequate packaging. This review highlights regulatory inconsistencies, limited surveillance, and underuse of metal speciation analysis, which hinder accurate toxicity assessment. Advances in trace-level HM detection systems are discussed in terms of sensitivity, accessibility, and feasibility. Studies from diverse geographic regions frequently report high levels of Pb and Cd in samples originating from industrialized areas in low- and middle-income countries. Health risk indicators, such as target hazard quotients (THQs) and margins of exposure (MOEs), often exceed safety thresholds, particularly in children, indicating significant public health risks, especially with prolonged exposure. These findings underscore the urgent need for systematic contaminant monitoring, harmonized regulations, source-focused mitigation policies, and investment in rapid, cost-effective testing technologies to safeguard milk and dairy product safety worldwide.
- 10 September 2025
- Published by MDPI AG in Pollutants
- Vol. 5 (3) , 29
Open AccessHeavy Metals in Milk and Dairy Products: Safety and Analysis
Milk and dairy products play a key role in the human diet but may also be vehicles for toxic contaminants, particularly heavy metals and metalloids (HMs), such as lead (Pb), cadmium (Cd), mercury (Hg), and arsenic (As). This integrative review examines peer-reviewed studies published between 2015 and 2025 to examine sources, occurrence, and health risks associated with HM contamination in milk and dairy products. Key sources include industrial emissions, agricultural runoff, contaminated feed and water, and inadequate packaging. This review highlights regulatory inconsistencies, limited surveillance, and underuse of metal speciation analysis, which hinder accurate toxicity assessment. Advances in trace-level HM detection systems are discussed in terms of sensitivity, accessibility, and feasibility. Studies from diverse geographic regions frequently report high levels of Pb and Cd in samples originating from industrialized areas in low- and middle-income countries. Health risk indicators, such as target hazard quotients (THQs) and margins of exposure (MOEs), often exceed safety thresholds, particularly in children, indicating significant public health risks, especially with prolonged exposure. These findings underscore the urgent need for systematic contaminant monitoring, harmonized regulations, source-focused mitigation policies, and investment in rapid, cost-effective testing technologies to safeguard milk and dairy product safety worldwide.
- 1 July 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Trace Elements and Electrolytes
- Vol. 40 (07) , 126-138
Metal chelators as part of a strategy for the treatment of neurodegenerative diseases
- 1 July 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Trace Elements and Electrolytes
- Vol. 40 (07) , 126-138
Metal chelators as part of a strategy for the treatment of neurodegenerative diseases
- 1 January 2023
- Published by Springer Nature in Neurophysiology
- Vol. 55 (1-2) , 8-30
Bioactive compounds from marine macroalgae in the treatment and prevention of neurodegenerative diseases
- 1 January 2023
- Published by Springer Nature in Neurophysiology
- Vol. 55 (1-2) , 8-30
Bioactive compounds from marine macroalgae in the treatment and prevention of neurodegenerative diseases
- 1 January 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Trace Elements and Electrolytes
- Vol. 40 (01) , 1-22
The influence of the biometals Cu, Fe, and Zn and the toxic metals Cd and Pb on human health and disease
- 1 January 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Trace Elements and Electrolytes
- Vol. 40 (01) , 1-22
The influence of the biometals Cu, Fe, and Zn and the toxic metals Cd and Pb on human health and disease
- Open Access
- 28 March 2020
- Published by Guarda Polytechnic Institute in Egitania Sciencia
- Vol. 2 (25) , 37-49
TEOR DE SAL DOS CEREAIS DE PEQUENO-ALMOÇO E A SUA CONTRIBUIÇÃO PARA O VALOR DE REFERÊNCIA
TEOR DE SAL DOS CEREAIS DE PEQUENO-ALMOÇO E A SUA CONTRIBUIÇÃO PARA O VALOR DE REFERÊNCIA
- 28 March 2020
- Published by Guarda Polytechnic Institute in Egitania Sciencia
- Vol. 2 (25) , 37-49
Open AccessTEOR DE SAL DOS CEREAIS DE PEQUENO-ALMOÇO E A SUA CONTRIBUIÇÃO PARA O VALOR DE REFERÊNCIA
TEOR DE SAL DOS CEREAIS DE PEQUENO-ALMOÇO E A SUA CONTRIBUIÇÃO PARA O VALOR DE REFERÊNCIA
- 1 January 2020
- Published by Springer Nature in Neurophysiology
- Vol. 52 (1) , 80-88
Roles of Metal Microelements in Neurodegenerative Diseases
- 1 January 2020
- Published by Springer Nature in Neurophysiology
- Vol. 52 (1) , 80-88
Roles of Metal Microelements in Neurodegenerative Diseases